

Press Release

Zug, 21 September 2010

Successful sale of Asthmatx, a company from HBM BioVentures' portfolio, to Boston Scientific increases liquidity by CHF 4 million

Privately-owned, California (USA)-based Asthmatx Inc., which has been part of the HBM BioVentures Ltd (SIX: HBMN) portfolio since 2005, has approved a takeover by Boston Scientific, Inc. (NYSE: BSX), a global medical technology company. Boston Scientific will pay Asthmatx shareholders USD 193.5 million in cash, corresponding to almost twice the amount invested. Additional payments of up to USD 250 million will fall due when future sales milestones are reached, which would take the total return to a maximum of 4.5 times the investment made.

HBM BioVentures is a major investor in Asthmatx and has played a significant role in the company's growth since its initial investment in 2005. In 2007, Asthmatx received USD 50 million from Olympus for the continued financing of its product development activities. Following on from positive trial data in the spring of 2009, the FDA approved the Alair System for sale in April 2010. Boston Scientific's cash payment for the Asthmatx takeover amounts to almost twice HBM BioVentures' original investment. Further significant profit potential exists in the form of future milestone payments, which are dependent on sales of the Alair system. In the best case, the total proceeds from the investment will be 4.5 times the amount invested.

Asthmatx is a medical device company that develops and manufactures catheter-based medical devices for patients with severe asthma. Asthmatx's bronchial thermoplasty, delivered by the Alair System, is a novel device-based treatment option for patients with severe asthma. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under moderate sedation and the patient typically returns home the same day. The Alair System has been approved for use in the US by the FDA and has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com or www.BTforAsthma.com.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



HBM BioVentures Ltd

As a venture capital company, HBM BioVentures invests world-wide in some 35 mature young companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies, Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SWX Swiss Exchange (ticker: HBMN). Visit www.hmbioventures.com.

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hmbioventures.com
www.hmbioventures.com